Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Australian company receives first prescription in UK, and cultivation and manufacturing facility permit in AU

Australian medicinal cannabis company Althea Group Holdings Limited wholly owned subsidiary, Althea MMJ UK Ltd, has received its first patient prescription in the United Kingdom (UK) for Althea medicinal cannabis. Further to this, a planning permit has been issued by Frankston City Council for Althea’s Australian cultivation and manufacturing facility.

"The receipt of the first prescription in the UK is the result of many months work, since Althea’s February 2019 announcement that it had entered the highly regulated UK market," the team with the company explains. "We expect to receive more patient prescriptions in the coming days and will export Althea products from Australia, in order to satisfy demand." 

Althea CEO Josh Fegan said: “We are excited to have received our first prescription for Althea medicinal cannabis in the UK. We are familiar with the significance of achieving a first prescription from our experience in Australia, where Althea recently surpassed the 1,000-patient milestone. The preparation and work which has resulted in our first prescription cannot be underestimated. From small things, big things grow.”

According to the company, the UK will create a second significant distribution channel for Althea’s current and future Australian manufactured, medicinal cannabis products.

The UK announcement comes at the same time the planning permit was granted for Althea’s fully funded Victorian-based, Office of Drug Control (ODC) approved, cultivation and manufacturing facility. The permit is the culmination of a process which involved both the Victorian State Government and Frankston City Council and represents significant progress for the project.

Althea Director of Cultivation Daniel Mansfield said: “The Althea production team is excited following the granting of the planning permit for the Skye manufacturing and cultivation facility. It has been an absolute pleasure working closely with Aphria, Inc on the design of this world-class facility, along with many Australian based consultants. We will continue to work toward our goal of meeting a 2020 production target, as we progress to the next goal of obtaining our building permit.”

The granting of the planning permit and receipt of its first prescription in the UK follows Althea’s recent 1,000 patient milestone in Australia announcement, adding to the company’s growth momentum.

Mr Fegan added: “Althea is very pleased to be able to provide an update regarding our fully funded, ODC approved cultivation and manufacturing facility. I would like to thank the Victorian Government, and in particular Invest Victoria, as well as the Frankston City Council. Operating within such a highly regulated industry requires constant interaction with all levels of government and this permit represents the success of industry working with government.” 

For more information:
Althea Group Holdings
Josh Fegan, CEO & Managing Director
[email protected]   

Publication date: